Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Journavx is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Alpine Immune Sciences Inc. appears in 1 tracked Biotech story from March 10, 2026.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Journavx is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Alpine Immune Sciences Inc. appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alpine Immune Sciences Inc.. Shared-story counts are live from our verified record — not editorial picks.
Potential Approval
Estimated approval date based on 6-month priority review timeline.
FDA Filing Deadline
Target date for completing the BLA application for accelerated approval.
Phase 3 Success
Vertex announces povetacicept met primary endpoint in IgA nephropathy trial.
Alpine Acquisition
Vertex acquires Alpine Immune Sciences for $4.9B to obtain povetacicept.
Vertex Pharmaceuticals reported that its Phase 3 trial for povetacicept met its primary endpoint, showing a 52% reduction in proteinuria for patients with IgA nephropathy. The company plans to file for FDA accelerated approval by the end of March 2026, utilizing a priority review voucher to expedite the process.
Alpine Immune Sciences Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
